Multiple Myeloma Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Multiple Myeloma stocks.

Multiple Myeloma Stocks Recent News

Date Stock Title
Nov 20 CRBU Caribou Biosciences to Participate in Upcoming Investor Conferences
Nov 19 BMY Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
Nov 19 BMY Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
Nov 18 BMY Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Nov 18 STRO Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know
Nov 18 BMY Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?
Nov 18 BMY EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
Nov 17 BMY Bristol-Myers Squibb: Buy This Bargain Before It's Gone
Nov 17 CASI CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
Nov 17 BMY Large Pension Doubled Palantir Stake, Bought Up Intel and CVS Stock
Nov 15 BMY Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS
Nov 15 BMY Bristol Myers gets positive EMA opinion for repotrectinib
Nov 15 TSVT US$8.25: That's What Analysts Think 2seventy bio, Inc. (NASDAQ:TSVT) Is Worth After Its Latest Results
Nov 15 BMY Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Nov 15 CASI CASI Pharmaceuticals reports Q3 results
Nov 15 CASI CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
Nov 15 BMY Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
Nov 15 STRO Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Nov 15 CGEN Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Nov 14 BMY Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
Multiple Myeloma

Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. Often, no symptoms are noticed initially. When advanced, bone pain, bleeding, frequent infections, and anemia may occur. Complications may include amyloidosis.The cause is unknown. Risk factors include obesity, radiation exposure, family history, and certain chemicals. The underlying mechanism involves abnormal plasma cells producing abnormal antibodies which can cause kidney problems and overly thick blood. The plasma cells can also form a mass in the bone marrow or soft tissue. When only one mass is present, it is known as a plasmacytoma, while more than one is known as multiple myeloma. Multiple myeloma is diagnosed based on blood or urine tests finding abnormal antibodies, bone marrow biopsy finding cancerous plasma cells, and medical imaging finding bone lesions. Another common finding is high blood calcium levels.Multiple myeloma is considered treatable, but generally incurable. Remissions may be brought about with steroids, chemotherapy, targeted therapy, and stem cell transplant. Bisphosphonates and radiation therapy are sometimes used to reduce pain from bone lesions.Globally, multiple myeloma affected 488,000 people and resulted in 101,100 deaths in 2015. In the United States, it develops in 6.5 per 100,000 people per year and 0.7% of people are affected at some point in their lives. It usually occurs around the age of 61 and is more common in men than women. It is uncommon before the age of 40. Without treatment, typical survival is seven months. With current treatments, survival is usually 4–5 years. This gives a five-year survival rate around 49%. The word myeloma is from the Greek myelo- meaning "marrow" and -oma meaning "tumor".

Browse All Tags